Cel
Leukodystrophies (LDs) are inherited rare neurodegenerative diseases of the white matter and its main component, the myelin, that are affecting predominantly children. Severity of the disease is related to the axonal dysfunction due to myelin deficiency or destruction. Despite the achievement of remarkable advances made in the past decade, there is no current curative therapy. The development of therapeutic approaches for myelin repair and neuroprotection constitutes the main objective of the LeukoTreat project. Indeed LDs constitute prototypic pathologies to tackle myelin formation/destruction issues as well as glial cells dysfunctions in neurodegeneration. The global aim is to promote the development of therapeutic strategies for the largest number of LD affected patients and further applications to more common white matter disorders and finally neurodegenerative diseases. For this purpose, the project will combine the expertise of (i) recognized European research teams in the field of White Matter diseases (COST Myelinet), (ii) high-technology SMEs, (iii) experts in medical ethics and (iv) LD patients and families associations. To develop efficient therapies, the LeukoTreat project is based on 5 complementary approaches consisting in: (i) collecting information on the epidemiology, the natural history, the genotype/phenotype correlation of LDs for at least 500 patients; (ii) validating/identifying biomarkers for therapeutic decisions/follow up to isolate new therapeutic targets; (iii) developing pharmacological strategies with the ultimate objective to launch at least 4 pharmacological clinical trials during 5 years following the project; (iv) developing innovative gene and cell therapies with the ultimate objective to launch at least 3 clinical trials during the next 5 years; (v) tackling ethical impacts of the proposed therapeutic challenges by integrating the participation of patients driven by a well-experienced research team strongly skilled in ethics
Dziedzina nauki
Zaproszenie do składania wniosków
FP7-HEALTH-2009-single-stage
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
CP-FP - Small or medium-scale focused research projectKoordynator
63001 Clermont-Ferrand
Francja
Zobacz na mapie
Uczestnicy (24)
00165 Roma
Zobacz na mapie
16147 Genova
Zobacz na mapie
53127 Bonn
Zobacz na mapie
75654 Paris
Zobacz na mapie
63360 Saint-Beauzire
Zobacz na mapie
M13 9PL Manchester
Zobacz na mapie
08908 L'Hospitalet De Llobregat
Zobacz na mapie
80539 Munchen
Zobacz na mapie
1090 Wien
Zobacz na mapie
13288 MARSEILLE CEDEX 9
Zobacz na mapie
WC1E 6BT LONDON
Zobacz na mapie
20132 MILANO
Zobacz na mapie
1105AZ Amsterdam
Zobacz na mapie
75270 cedex 06 Paris
Zobacz na mapie
75008 Paris
Zobacz na mapie
54520 Laxou
Zobacz na mapie
CB2 1TN Cambridge
Zobacz na mapie
F-75205 / 13 Paris
Zobacz na mapie
20133 Milano
Zobacz na mapie
Zakończenie uczestnictwa
55131 Mainz
Zobacz na mapie
20251 Hamburg
Zobacz na mapie
72074 Tuebingen
Zobacz na mapie
2052 Sydney
Zobacz na mapie
20132 Milano
Zobacz na mapie